NVAX Prakiraan wutah bathi resik saben saham kanggo taun ngarep Novavax

Is it worth investing in Novavax, Inc. (NVAX), given the acceleration of vaccine development through AI protein modeling? The GURU.Markets terminal displays a chart of the forward net income growth rate, where the current reading is -761.80. The business model is based on US R&D centers with outsourced manufacturing. Meanwhile, John Jacobs' management has successfully stabilized the company through licensing agreements, restoring market confidence.

Novavax Corp (NVAX): Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep saka 04.07.2022 nganti 15.11.2026

Rincian metrik komprehensif lan analitis Novavax (NVAX)

- kuotasi lan prakiraan analis:

Kutipan saham Novavax Pharma|NVAX - Prakiraan konsensus analis

- data kapitalisasi pasar:

Nilai pasar Novavax Pharma|NVAX - Rega Tumbas Perusahaan

- rincian nilai buku perusahaan:

Aset Bersih saben Siji Saham Novavax|NVAX - Kapitalisasi Akuntansi|Rasio Nilai Pasar marang Nilai Buku novavax.com|NVAX - Aset Perusahaan

- data utang lan likuiditas:

- data bathi resik lan rasio valuasi:

NVAX - Bathi perusahaan|Bathi mangsa ngarep Novavax, Inc.|NVAX - Nilai perusahaan marang bathi resik|Pangali Forward P/E Novavax Inc|NVAX - Kapitalisasi marang bathi resik kanthi nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Novavax Pharma|NVAX - Bathi operasional sadurunge amortisasi|Bathi resik saben saham (EPS TTM) Novavax|NVAX - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan novavax.com|NVAX - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Novavax, Inc.

- rincian pendapatan lan dodolan emiten:

NVAX - Volume dodolan perusahaan|Volume dodolan mangsa ngarep perusahaan Novavax, Inc.|NVAX - Rasio rega marang pendapatan|Multiplikator Forward P/S Novavax, Inc.

Analisis dhasar perusahaan:Novavax, Inc.

This indicator measures the expected percentage difference between current and future net earnings per share, reflecting the market's implied rate of business expansion. The trend in consensus EPS forecasts for the coming year for Novavax, Inc. (NVAX) demonstrates the company's ability to monetize the transition to combination vaccines and new partnerships, determining the long-term sustainability of share prices amid the saturation of the monovalent vaccine market.

Pesaing wigati